Heat Biologics (HTBX) Provides Update on COVID-19 Vaccine Efforts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2023
- S&P 500, Nasdaq notch biggest weekly losses since March
- S&P 500 could end the year over 10% higher from here - Piper Sandler
- Citi says Meta shares to rally in near term on share gains, upcoming AI event
- Ads are coming to Amazon Prime Video next year; Stock pops
- 'Sell the last rate hike' strategy is in action, stocks could fall further - BofA's Hartnett
- Nikola (NKLA) Announces $40M Notes Offering
- Apple (AAPL) unveils iPhone 15 Pro and iPhone 15 Pro Max
- What to know about India's Chandrayaan-3 moon landing mission
- Explainer-Who was Hardeep Singh Nijjar whose death fuelled India-Canada tensions?
- Reactions as India's Chandrayaan-3 makes historic moon landing
- Activision Blizzard, Roku, Wayfair and Citi rise premarket; Ford falls
- After-hours movers: U.S. Steel gains on new bidder, Scholastic falls following results
- FedEx, Splunk and Marvell rise premarket; Cisco, Broadcom fall
- Coty and General Mills rise premarket; Instacart, Chewy and Dollar General fall
- After-hours movers: Nano Dimension gains on buyback resumption, Steelcase up on EPS
Heat Biologics Provides Update on COVID-19 Vaccine Efforts
June 4, 2020 7:31 AM EDTOn track to complete vaccine development and initiate manufacturing in August
DURHAM, NC / ACCESSWIRE / June 4, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including a novel COVID-19 vaccine and multiple oncology product candidates, today announced further progress on its COVID-19 vaccine program.
Jeff Hutchins, Chief Scientific and Operating Officer of Heat, stated, "I am pleased to report important advancements related to our COVID-19 vaccine program. Specifically, we have achieved stable co-expression of gp96/nCoV-S... More
